Study Demonstrates That Clinical Assessments of Fluid Status Are Often Inaccurate, Highlighting the Urgent Need for BVA and Other More Reliable Tools in Landmark Pilot Study Oak Ridge, TN, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today highlighted the significant findings of a new pilot study published in the Journal of Critical Care. Co-authored by leading intensive care expert Jan Bakker, M.D., Ph.D., this pivotal researc ...

Core Viewpoint - Nuwellis, Inc. has signed a non-binding letter of intent to acquire Rendiatech, Ltd., aiming to enhance its fluid management technology offerings, particularly in continuous renal health monitoring [1][3]. Company Overview - Nuwellis, Inc. is a medical technology company focused on improving patient outcomes through advanced fluid management, currently commercializing the Aquadex SmartFlow system for ultrafiltration therapy [7]. - Rendiatech, Ltd. specializes in real-time urine flow and acute kidney injury monitoring technologies, with its key product being the Clarity RMS, an FDA-cleared critical care monitoring system [6]. Proposed Acquisition Details - The acquisition will potentially add Rendiatech's Clarity RMS and the next-generation Clarity Prime system to Nuwellis' product portfolio, enhancing real-time urine monitoring capabilities [2][5]. - The transaction is expected to close in the fourth quarter of 2025, pending due diligence and final Board approval [5]. Strategic Importance - The acquisition aligns with Nuwellis' growth strategy to achieve cash flow positivity and enhance its comprehensive fluid management offerings [3]. - Real-time urine output monitoring is critical for detecting acute kidney injury (AKI), which affects 10% to 20% of emergency hospital admissions, with higher rates in ICU settings [4]. Market Impact - The integration of Rendiatech's technologies is anticipated to improve clinical outcomes through earlier detection of AKI and dehydration, particularly in complex ICU patients [4].

Core Points - Nuwellis, Inc. announced that stockholders approved all proposals at the Special Meeting, aimed at enhancing financial flexibility and supporting strategic growth [1][2][3] Proposal Summaries - **Warrant Exercise Proposal**: Stockholders approved the issuance of common stock shares through the exercise of warrants from the June 10, 2025 financing, allowing full access to committed capital [1] - **Authorized Shares Increase Proposal**: An amendment was approved to increase the number of authorized shares of common stock from 100 million to 200 million [2] - **Reverse Split Proposal**: Stockholders approved a reverse stock split at a ratio between 1-for-5 and 1-for-70, to be enacted at the Board's discretion for Nasdaq compliance [2] Company Insights - CEO John Erb expressed appreciation for stockholder support, indicating that these approvals are crucial for strengthening the company's capital position and executing long-term strategy [3] - Nuwellis is focused on transforming the lives of patients with fluid overload through its Aquadex SmartFlow® system, which is designed for ultrafiltration therapy [4][5]